Pharmaxis’ CF Drug Bronchitol Gets Thumbs Down From FDA Panel

Advisory committee members said pediatric efficacy and safety concerns precluded approval of dry powder mannitol for the broad indication of improving pulmonary function in cystic fibrosis patients ages six years and older.